Clinical Trial Update: Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lomitapide in pediatric patients with homozygous familial hypercholesterolemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• Lomitapide (lomitapide)

Snippet

Sponsor: Aegerion Pharmaceuticals, Inc. | Conditions: Homozygous Familial Hypercholesterolemia | Phase 3 | Status: WITHDRAWN